NASDAQ$NUVL
Nuvalent Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Pipeline progress was highlighted, key anticipated milestones were reiterated, and financial results for the first quarter of 2024 were reported.
Nuvalent reported its Q1 2024 financial results, highlighting pipeline progress and reiterating key milestones. The company's cash position is strong, with an operating runway anticipated into 2027. Clinical updates from the ARROS-1 and ALKOVE-1 trials are expected in the second half of 2024, and the first patient in the HER2 program is expected to be dosed this year.
- Nuvalent is on track for a potential first approval in 2026.
- Updated data from the ARROS-1 Phase 1/2 trial is expected at a medical meeting in the second half of 2024.
- Updated data from the ALKOVE-1 trial is expected at a medical meeting in the second half of 2024.
- The company expects to initiate the Phase 1 trial for its HER2 program in 2024.
Headline financials
Revenue & EPS history
Nuvalent · Revenue · Quarterly
$0
Forward guidance
Nuvalent's OnTarget 2026 plan outlines key milestones throughout 2024, leading to potential pivotal data in 2025 and a first potential approved product in 2026.
Tailwinds
- Progress the Phase 2 portion of its ARROS-1 trial of zidesamtinib in patients with advanced ROS1-positive NSCLC with registrational intent.
- Initiate the Phase 2 portion of its ALKOVE-1 trial of NVL-655 in patients with advanced ALK-positive NSCLC with registrational intent.
- Launch the front-line development strategy for its ALK program.
- Present interim data from its ongoing ARROS-1 and ALKOVE-1 clinical trials at medical meetings.
- Initiate the Phase 1 trial for its HER2 program.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2024
-0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-7.7%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+14.6%
Q4 2021
Best reaction
-5.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.5% | -4.1% | -7.5% | |
| Q3 2025 | -5.0% | -11.6% | +6.2% | |
| Q1 2025 | +3.2% | +3.7% | +10.2% | |
| Q4 2024 | -2.8% | -7.0% | -5.2% | |
| Q3 2024 | -4.3% | -8.0% | -8.0% | |
| Q1 2024 | -3.1% | +0.7% | +17.2% | |
| Q4 2023 | -1.4% | +0.6% | -13.3% | |
| Q3 2023 | +3.7% | +5.0% | +38.8% | |
| Q2 2023 | -1.1% | -3.1% | +9.2% | |
| Q1 2023 | -2.5% | -1.1% | +3.5% | |
| Q4 2022 | +8.3% | +4.7% | +0.9% | |
| Q3 2022 | +1.0% | +2.9% | -2.1% | |
| Q2 2022 | +4.5% | +9.3% | +13.1% | |
| Q1 2022 | -0.7% | +7.3% | +16.1% | |
| Q4 2021 | +14.6% | +20.2% | -8.1% | |
| Q3 2020 | +1.3% | -14.7% | -2.4% | |
| Q3 2021 | +1.3% | -10.4% | -20.1% | |
| Q2 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2021 | -4.3% | -2.9% | -52.6% | |
| Q2 2021 | -4.3% | -2.9% | -52.6% | |
| Q4 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro